Inspire Investing LLC Acquires New Shares in Kymera Therapeutics, Inc. $KYMR

Inspire Investing LLC acquired a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 3rd quarter, Holdings Channel reports. The firm acquired 4,316 shares of the company’s stock, valued at approximately $482,000.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Kymera Therapeutics in the 2nd quarter valued at $635,067,000. Merck & Co. Inc. acquired a new position in shares of Kymera Therapeutics during the second quarter worth about $88,544,161. Bank of America Corp DE acquired a new position in shares of Kymera Therapeutics during the second quarter worth about $43,378,000. Braidwell LP boosted its position in shares of Kymera Therapeutics by 12.0% in the second quarter. Braidwell LP now owns 378,163 shares of the company’s stock worth $43,364,000 after buying an additional 40,604 shares during the period. Finally, Jennison Associates LLC boosted its position in shares of Kymera Therapeutics by 2.5% in the first quarter. Jennison Associates LLC now owns 508,999 shares of the company’s stock worth $42,395,000 after buying an additional 12,334 shares during the period.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the sale, the insider owned 50,254 shares in the company, valued at $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. This represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. 15.98% of the stock is currently owned by company insiders.

Kymera Therapeutics Stock Up 3.3%

KYMR stock opened at $126.63 on Friday. Kymera Therapeutics, Inc. has a 52-week low of $55.66 and a 52-week high of $130.05. The stock’s 50 day moving average is $114.93 and its two-hundred day moving average is $96.35. The company has a market capitalization of $10.53 billion, a PE ratio of -34.98 and a beta of 1.98.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.06). The company had revenue of $1.35 million during the quarter, compared to analyst estimates of $3.28 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 22.65%. The company’s revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.94) earnings per share. As a group, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.90 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on KYMR shares. Stifel Nicolaus increased their target price on Kymera Therapeutics from $132.00 to $152.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. Truist Financial reaffirmed a “buy” rating and issued a $150.00 price objective (up from $136.00) on shares of Kymera Therapeutics in a research report on Friday. Oppenheimer reiterated an “outperform” rating and set a $140.00 price objective on shares of Kymera Therapeutics in a research note on Thursday. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a research note on Thursday. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Kymera Therapeutics in a research report on Thursday, July 30th. They set a “hold” rating and a $120.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and an average target price of $137.92.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, showing deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers, and a favorable safety profile. The data support continued development of the company’s immunology pipeline. Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: Truist Financial reaffirmed its “buy” rating and raised its price target from $136 to $150, implying further upside based on the current trading level. Truist Securities Adjusts Price Target on Kymera Therapeutics
• Positive Sentiment: BTIG Research raised its target from $134 to $139 and maintained a “buy” rating, adding to the favorable analyst sentiment.
• Neutral Sentiment: Kymera provided a Phase 1 update on the formulation study for KT-621, offering investors additional information on the program’s ongoing clinical development. KT-621 Formulation Study Update
• Neutral Sentiment: RBC increased its price target from $112 to $116 but retained a “sector perform” rating, signaling limited conviction at the current valuation.
• Negative Sentiment: Third-quarter results missed expectations: adjusted loss was $1.32 per share versus a $1.26 consensus loss, while revenue of $1.35 million was below the $3.28 million estimate. The net loss also widened year over year, highlighting ongoing cash-burn and execution risks. Kymera Therapeutics Q3 Net Loss Widens

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.